Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 12.63 is in line with its 3-year average of 12.49, around the middle of its 3-year range (0.00–32.67).
As of the fiscal period ended Tuesday, June 30, 2026. 10.05% above its 12-month average of 11.48.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 12.63.
QUICK RATIO (ACID-TEST)
12.63
QUICK RATIO (ACID-TEST) AVG TTM
11.48
QUICK RATIO (ACID-TEST) AVG 3Y
12.49
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.05%
CURRENT VS 3Y AVG
+1.08%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.85
median of 440 covered companies
CURRENT VS SECTOR MEDIAN
+343.12%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$114.24M
Quick Ratio (Acid-Test)
12.63
TTM Avg
11.48
3Y Avg
12.49
5Y Avg
N/A
Market Cap
$113.77M
Quick Ratio (Acid-Test)
13.40
TTM Avg
10.04
3Y Avg
7.53
5Y Avg
8.95
Market Cap
$116.59M
Quick Ratio (Acid-Test)
2.39
TTM Avg
3.50
3Y Avg
2.69
5Y Avg
1.97
Market Cap
$111.17M
Quick Ratio (Acid-Test)
7.28
TTM Avg
6.67
3Y Avg
7.13
5Y Avg
10.02
Market Cap
$117.43M
Quick Ratio (Acid-Test)
3.36
TTM Avg
3.23
3Y Avg
4.24
5Y Avg
6.08
Market Cap
$118.02M
Quick Ratio (Acid-Test)
6.49
TTM Avg
6.44
3Y Avg
8.52
5Y Avg
8.53
Market Cap
$118.50M
Quick Ratio (Acid-Test)
1.98
TTM Avg
1.40
3Y Avg
1.60
5Y Avg
1.70
Market Cap
$109.93M
Quick Ratio (Acid-Test)
5.05
TTM Avg
1.26
3Y Avg
3.46
5Y Avg
6.50
Market Cap
$118.63M
Quick Ratio (Acid-Test)
0.65
TTM Avg
1.74
3Y Avg
2.55
5Y Avg
2.19
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $114.24M | 12.63 | 11.48 | 12.49 | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | 13.40 | 10.04 | 7.53 | 8.95 |
| Genelux Corporation (GNLX)vs › | $116.59M | 2.39 | 3.50 | 2.69 | 1.97 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | 7.28 | 6.67 | 7.13 | 10.02 |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | 3.36 | 3.23 | 4.24 | 6.08 |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | 6.49 | 6.44 | 8.52 | 8.53 |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | 1.98 | 1.40 | 1.60 | 1.70 |
| Immunic, Inc. (IMUX)vs › | $109.93M | 5.05 | 1.26 | 3.46 | 6.50 |
| BGM Group Ltd. (BGM)vs › | $118.63M | 0.65 | 1.74 | 2.55 | 2.19 |
| Apyx Medical Corporation (APYX)vs › | $109.49M | 4.53 | 4.41 | 4.05 | 4.51 |
Quick Ratio
12.63
Excludes inventory
Current Ratio
12.63
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 12.63 |
| 2026-03-31 | 8.06 |
| 2025-12-31 | 10.61 |
| 2025-09-30 | 12.03 |
| 2025-06-30 | 14.04 |
| 2025-03-31 | 25.86 |
| 2024-12-31 | 15.05 |
| 2024-09-30 | 31.65 |
| 2024-06-30 | 32.67 |
| 2024-03-31 | 0.00 |
| 2023-12-31 | 7.50 |
| 2023-09-30 | 0.00 |
